Report Overview

Spectra's World Market for Gynaecology, 2007-2017 provides a unique assessment of current developments and prospective factors that will shape the global female health market over the next decade. This unrivalled, in-depth market research study commissioned by one of the top three multinational pharmaceutical companies presents a detailed and comprehensive analysis of prescription products used in the diverse areas of infertility, contraception, gynaecological disorders, and menopause.

The market for gynaecology is predicated on hormonal drugs that have recently been subject to controversy based on reports of associated increased risks of cardiovascular disease and cancer. The global market has suffered as a consequence due to cautious prescribing approaches for hormone replacement therapies.

The pipeline however is vast with over 75 hormonal products in clinical development that will offer purer analogues, low-dose formulations, new delivery modes and formats, novel mechanisms of action, and which also confer sophisticated clinical effects over traditional products.

The market for gynaecology is showing signs of a significant upward growth trend over the forecast period to 2017 and the next decade will be exciting, but companies will need to differentiate their products and consider the market forces that may affect product revenue and portfolios.

The World Market for Gynaceology aims to provide an expert analysis of the prescription drug market for female health over the next decade based on current industrial insights, market factors and forces, and trend information. Study objectives include critical assessments of existing products, reviews of products in clinical development, therapy forecasting of product/portfolios to 2017, and market sector analytics by therapeutic category and discrete disorder.